REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS

Detalles Bibliográficos
Autores principales: WILLIAMS, STEPHANIE N, WALO JR, RICHARD, LATTANZIO, NATALIA, DAWKINS, KEVIN, K ABDELAL, QASSEM, HAMAD, KAREN, WIESE-ROMETSCH, WILHELMINE
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American College of Chest Physicians. Published by Elsevier Inc. 2022
Materias:
Critical Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548756/
http://dx.doi.org/10.1016/j.chest.2022.08.707

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9548756/
http://dx.doi.org/10.1016/j.chest.2022.08.707

Ejemplares similares